These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 893736)

  • 21. Pharmacokinetics of moxalactam in elderly subjects.
    Andritz MH; Smith RP; Baltch AL; Griffin PE; Conroy JV; Sutphen N; Hammer MC
    Antimicrob Agents Chemother; 1984 Jan; 25(1):33-6. PubMed ID: 6703682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nizatidine disposition in subjects with normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Bopp RJ; Sloan RS; Callaghan JT
    Clin Pharmacol Ther; 1988 Jun; 43(6):688-95. PubMed ID: 2897890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of the bioavailability of pindolol in malabsorption syndromes.
    Evard D; Aubry JP; Le Quintrec Y; Cheymol G; Cheymol A
    Br J Clin Pharmacol; 1984 Oct; 18(4):632-7. PubMed ID: 6487506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of renal function on the bioavailability of ciprofloxacin.
    Plaisance KI; Drusano GL; Forrest A; Weir MR; Standiford HC
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1031-4. PubMed ID: 2393263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function.
    Lanao JM; Domínguez-Gil A; Tabernero JM; De Castro S
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):171-5. PubMed ID: 447438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of pindolol absorption in malabsorption syndromes].
    Evard D; Le Quintrec Y; Aubry JP; Cheymol G; Cheymol A
    Gastroenterol Clin Biol; 1983 Apr; 7(4):398-404. PubMed ID: 6873552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.
    Gross AS; McLachlan AJ; Minns I; Beal JB; Tett SE
    Br J Clin Pharmacol; 2001 Jun; 51(6):547-55. PubMed ID: 11422014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.
    Marcantonio LA; Auld WH; Murdoch WR; Purohit R; Skellern GG; Howes CA
    Br J Clin Pharmacol; 1983 Feb; 15(2):245-52. PubMed ID: 6849758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism of pindolol in patients with renal failure.
    Ohnhaus EE; Heidemann H; Meier J; Maurer G
    Eur J Clin Pharmacol; 1982; 22(5):423-8. PubMed ID: 7117354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.
    Mangione A; Boudinot FD; Schultz RM; Jusko WJ
    Antimicrob Agents Chemother; 1982 Mar; 21(3):428-35. PubMed ID: 6213190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of cefoxitin in patients with normal or impaired renal function.
    Garcia MJ; Dominguez-Gil A; Tabernero JM; Sanchez Tomero JA
    Eur J Clin Pharmacol; 1979 Sep; 16(2):119-24. PubMed ID: 499308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency.
    Kampf D; Schurig R; Korsukewitz I; Brückner O
    Antimicrob Agents Chemother; 1981 Dec; 20(6):741-6. PubMed ID: 7325641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents.
    Meier J
    Am Heart J; 1982 Aug; 104(2 Pt 2):364-73. PubMed ID: 6125095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between pharmacokinetics and bioavailability of cefroxadine (CGP 9000) and renal function.
    Bergan T; Brodwall EK; Larsen EW
    Chemotherapy; 1983; 29(3):163-73. PubMed ID: 6872614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of toborinone in subjects with congestive heart failure and concomitant renal impairment and/or concomitant hepatic impairment.
    Tammara B; Trang JM; Kitani M; Miyamoto G; Bramer SL
    J Clin Pharmacol; 2002 Dec; 42(12):1318-25. PubMed ID: 12463726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of melatonin in man: first pass hepatic metabolism.
    Lane EA; Moss HB
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1214-6. PubMed ID: 4055987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data.
    Hinderling PH
    Biopharm Drug Dispos; 2003 Jan; 24(1):1-16. PubMed ID: 12516074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.
    Larsson R; Erlanson P; Bodemar G; Walan A; Bertler A; Fransson L; Norlander B
    Br J Clin Pharmacol; 1982 Feb; 13(2):163-70. PubMed ID: 7059413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.